Catalyst Pharmaceuticals (CPRX) Tops Q2 EPS by 29c ; Offers Guidance

Catalyst Pharmaceuticals (NASDAQ: CPRX) reported Q2 EPS of $0.68, $0.29 better than the analyst estimate of $0.39. Revenue for the quarter came in at $146.54 million versus the consensus estimate of $140.22 million.

GUIDANCE:

Catalyst Pharmaceuticals sees FY2025 revenue of $545-565 million, versus the consensus of $560.7 million.

For earnings history and earnings-related data on Catalyst Pharmaceuticals (CPRX) click here.

You May Also Be Interested In

• HSBC Downgrades China Power International (2380:HK) (CPWIF) to Hold
• UBS Upgrades Apollo Tyres (APTY:IN) to Buy
• UBS Downgrades Klarna (KLAR) to Neutral